---
figid: PMC3107100__nor03901
figtitle: Genetic alterations in glioblastoma signal transduction pathways (adapted
  from Parsons et al)
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC3107100
filename: nor03901.jpg
figlink: /pmc/articles/PMC3107100/figure/NOR039F1/
number: F1
caption: Genetic alterations in glioblastoma signal transduction pathways (adapted
  from Parsons et al). (A) Proliferation and survival signaling is altered in 88%
  of glioblastomas. (B) p53 signaling is altered in 87% of glioblastomas. (C) RB signaling
  is altered in 78% of glioblastomas. CCND2 indicates cyclin-D2; CDK indicates cyclin-dependent
  kinase; CDKN indicates cyclin-dependent kinase inhibitor; EGFR indicates epidermal
  growth factor receptor; FOXO indicates forkhead box-O; HER2 indicates human epidermal
  growth factor receptor-2; NF1 indicates neurofibromin; PDGFR indicates platelet-derived
  growth factor receptor; PI3K indicates phosphatidylinositol 3-kinase; PTEN indicates
  phosphatase and tensin homolog; RB1 indicates retinoblastoma protein-1; and SRC*
  indicates activated (phosphorylated) SRC. Figure  is adapted from The Cancer Genome
  Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma
  genes and core pathways. Nature 2008;455(7216):1061–1068.
papertitle: 'Pathway inhibition: emerging molecular targets for treating glioblastoma.'
reftext: Wolfgang Wick, et al. Neuro Oncol. 2011 Jun;13(6):566-579.
year: '2011'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9001802
figid_alias: PMC3107100__F1
figtype: Figure
redirect_from: /figures/PMC3107100__F1
ndex: 3c4cf820-df01-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3107100__nor03901.html
  '@type': Dataset
  description: Genetic alterations in glioblastoma signal transduction pathways (adapted
    from Parsons et al). (A) Proliferation and survival signaling is altered in 88%
    of glioblastomas. (B) p53 signaling is altered in 87% of glioblastomas. (C) RB
    signaling is altered in 78% of glioblastomas. CCND2 indicates cyclin-D2; CDK indicates
    cyclin-dependent kinase; CDKN indicates cyclin-dependent kinase inhibitor; EGFR indicates
    epidermal growth factor receptor; FOXO indicates forkhead box-O; HER2 indicates
    human epidermal growth factor receptor-2; NF1 indicates neurofibromin; PDGFR indicates
    platelet-derived growth factor receptor; PI3K indicates phosphatidylinositol 3-kinase;
    PTEN indicates phosphatase and tensin homolog; RB1 indicates retinoblastoma protein-1;
    and SRC* indicates activated (phosphorylated) SRC. Figure  is adapted from The
    Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines
    human glioblastoma genes and core pathways. Nature 2008;455(7216):1061–1068.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Egfr
  - her
  - Hesr
  - dap
  - Src42A
  - Csk
  - Src64B
  - PEK
  - Pten
  - ras
  - Ras64B
  - Ras85D
  - Nf1
  - Akt
  - EGFR
  - CDKN2B
  - SRC
  - FGR
  - FYN
  - YES1
  - MDM2
  - EIF2AK3
  - PTEN
  - KRAS
  - HRAS
  - NRAS
  - NF1
  - TP63
  - AKT1
  - AKT2
  - AKT3
  - MDMA
  - Cancer
  - Lung cancer
---
